<DOC>
	<DOC>NCT00237120</DOC>
	<brief_summary>This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.</brief_summary>
	<brief_title>Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosed as Chronic Myelogenous Leukemia in Chronic Phase Previously untreated with Interferonalpha Performance status is normal or capable of only limited selfcare Patients who are pregnant or possibly pregnant Significant hepatic diseases Chronic Myelogenous Leukemia in advanced phase Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Imatinib</keyword>
	<keyword>CML</keyword>
</DOC>